Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients.
Imipenem-cilastatin was given in doses of 1 g intravenously every 6 h to 31 patients. Twenty-five patients, with 27 infections, were clinically evaluable and received 20 to 210 g of imipenem for a duration of 5 to 56 days (average 16.3 days). Infections included seven cases of osteomyelitis, seven o...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1985
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC180145/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/3860187/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.27.5.745 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|